Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTerpath-001: Adjuvant V940 (mRNA-4157) plus pembrolizumab vs placebo plus pembrolizumab in high-risk melanoma
jRCT2041230169Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing V940 (mRNA-4157) + pembrolizumab with Placebo + pembrolizumab (2 arms). Primary endpoint: Recurrence-Free Survival (RFS). Started Jun 2024; status: active, not recruiting.
02
Drugs
intismeran autogenepembrolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on jRCT2041230169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041230169.